Log In
BCIQ
Print this Print this
 

HTL18318

  Manage Alerts
Collapse Summary General Information
Company Sosei Group Corp.
DescriptionSelective muscarinic acetylcholine receptor M1 (CHRM1; HM1) agonist
Molecular Target Muscarinic acetylcholine receptor M1 (CHRM1) (HM1)
Mechanism of ActionMuscarinic acetylcholine receptor M1 agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationCognitive dysfunction
Indication DetailsImprove cognition in patients with dementia and schizophrenia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,340.0M

$125.0M

$3,165.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/07/2016

$3,340.0M

$125.0M

$3,165.0M

Get a free BioCentury trial today